Can sirolimus treat lymphangioma?

Sirolimus (sirolimus), also known as rapamycin, was first discovered in soil samples. It is a natural macrolide derived from the soil bacterium Streptomyces hygroscopicus. Sirolimus is a specific inhibitor of mammalian target of rapamycin (mTOR), a serine/threonine kinase that is a key factor in regulating angiogenesis, cell growth and proliferation.

Sirolimus was approved by the FDA as an oral immunosuppressant for kidney transplants in 1999 and in 2015 became the first drug to treat lymphangioleiomyomatosis, a rare disease characterized by progressive cystic lung disease, angiomyolipomas and lymphangioleiomyomas that primarily affects young women. Sirolimus therapy is used in the treatment of large lymphoid malformations due to its anti-angiogenic and anti-proliferative properties. In a previous systematic review, it could be demonstrated that sirolimus treatment has the potential to improve symptoms and reduce lymphatic malformations in different body parts.

SirolimusThe original drug has been launched in China and has entered the scope of Class B medical insurance. SpecificationsThe price of each box of 1mg*10 tablets is about 400 yuan. The domestic drug is only available to patients with anti-rejection reactions in organ transplantation. Patients who do not meet the conditions may not be able to purchase this drug. The original sirolimus drug has also been launched overseas. The price of the Turkish version of Specifications1mg*100 tablets per box is around RMB 2,000 (the price may fluctuate due to exchange rates). The ingredients of the original drugs marketed in China are basically the same as those of foreign original drugs. Currently, there are no generic sirolimus drugs produced in other countries.